Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.55 |
| ▸ | POLA1 | P09884 | 1/20 | 0.55 |
| ▸ | POLD1 | P28340 | 1/20 | 0.55 |
| ▸ | TK1 | P04183 | 7/20 | 0.52 |
| ▸ | NT5M | Q9NPB1 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154831 | 0.99 | POLB (0.57) | POLBPOLA1POLD1TK1NT5M | |
| Pyrophosphoric Acid SCHEMBL1269545 | 0.95 | POLB (0.54) | POLBPOLA1POLD1TK1NT5M | |
| Phosphoric Acid SCHEMBL3095605 | 0.91 | TK1 (0.52) | TK1DHFR | |
| SCHEMBL9549703 | 0.88 | TK1 (0.50) | POLBTK1DHFR | |
| Triphosphate SCHEMBL6066341 | 0.87 | POLB (0.58) | POLBPOLA1POLD1TK1 | |
| SCHEMBL19242604 | 0.87 | TK1 (0.53) | POLBTK1DHFR | |
| SCHEMBL78118 | 0.87 | TK1 (0.53) | POLBTK1DHFR | |
| Triphosphate SCHEMBL27892350 | 0.85 | POLB (0.61) | POLBPOLA1POLD1TK1 | |
| SCHEMBL709680 | 0.85 | POLB (0.57) | POLBPOLA1POLD1TK1 | |
| SCHEMBL9549708 | 0.85 | TK1 (0.48) | POLBTK1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114144529-B | Kit for genotyping | 因美纳有限公司 | 2025-04-29 | — | — | CN | claimed |
| EP-4253559-B1 | KITS FOR GENOTYPING | ILLUMINA INC (US) | 2025-04-02 | — | — | EP | claimed |
| EP-4527941-A2 | KITS FOR GENOTYPING | Illumina, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| WO-2025042729-A1 | CELL PREPARATION COMPOSITION, SYSTEM AND METHOD FOR SINGLE CELL TRANSCRIPTOMICS | Life Technologies Corporation (US) | 2025-02-27 | — | — | WO | claimed |
| EP-4479406-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | Promega Corporation (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240287502-A1 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2024-08-29 | — | — | US | claimed |
| US-20240102003-A1 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES | THERMO FISHER SCIENTIFIC BALTICS UAB (LT) | 2024-03-28 | — | — | US | claimed |
| EP-3969613-B1 | KITS FOR GENOTYPING | ILLUMINA INC (US) | 2023-10-04 | — | — | EP | claimed |
| EP-4253559-A2 | KITS FOR GENOTYPING | Illumina, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | PROMEGA CORPORATION | 2023-09-07 | — | — | US | claimed |
| EP-0496749-B1 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS (US) | 1995-12-06 | — | — | EP | claimed |
| EP-0679196-A1 | DNA SEQUENCING BY MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1995-11-02 | — | — | EP | claimed |
| US-5366860-A | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination | APPLIED BIOSYSTEMS, INC. (US) | 1994-11-22 | — | — | US | claimed |
| WO-1994016101-A2 | DNA SEQUENCING BY MASS SPECTROMETRY | KOESTER HUBERT (US) | 1994-07-21 | — | — | WO | claimed |
| EP-0496749-A4 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | — | 1993-06-16 | — | — | EP | claimed |
| EP-0496749-A1 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION. | APPLIED BIOSYSTEMS (US) | 1992-08-05 | — | — | EP | claimed |
| EP-0286418-B1 | ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEMS FOR THE SAME | US COMMERCE (US) | 1992-07-08 | — | — | EP | claimed |
| WO-1991005060-A2 | SPECTRALLY RESOLVABLE RHODAMINE DYES FOR NUCLEIC ACID SEQUENCE DETERMINATION | APPLIED BIOSYSTEMS, INC. (US) | 1991-04-18 | — | — | WO | claimed |
| WO-1988007854-A1 | NEW ANTI-RETROVIRAL AGENTS AND DELIVERY SYSTEM | UNITED STATES OF AMERICA, REPRESENTED BY THE UNITE (US) | 1988-10-20 | — | — | WO | claimed |
| EP-0286418-A1 | Anti-retroviral agents and delivery systems for the same | THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce (US) | 1988-10-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278968-A1 | OXAZINE DYES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION REACTIONS | POLRMT, POLB, POLN | POLB 2/4885POLA1 27/4885POLD1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.